{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:19Z","timestamp":1788262159268,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.blre.2026.101366","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:47:19Z","timestamp":1772095639000},"page":"101366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Underreported and underreviewed: Addressing the gaps in TKI tolerability literature for chronic myeloid leukemia"],"prefix":"10.1016","volume":"76","author":[{"given":"Dennis Dong Hwan","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Zackova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"De Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Isfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.blre.2026.101366_bb0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.blre.2026.101366_bb0010","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2026.101366_bb0015","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V13.5.6534","article-title":"CML no longer means early death","volume":"13","author":"Keel","year":"2016","journal-title":"Hematologist"},{"issue":"3","key":"10.1016\/j.blre.2026.101366_bb0020","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","article-title":"Chronic myelogenous leukemia: a concise update","volume":"82","author":"Kantarjian","year":"1993","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2026.101366_bb0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.blre.2026.101366_bb0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101366_bb0035","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-021-01260-y","article-title":"Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update","volume":"35","author":"Hughes","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2026.101366_bb0040","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41375-023-01888-y","article-title":"Health-related quality of life of patients with resistant\/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial","volume":"37","author":"Rea","year":"2023","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2026.101366_bb0045","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2400858","article-title":"Asciminib in newly diagnosed chronic myeloid leukemia","volume":"391","author":"Hochhaus","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2026.101366_bb0050","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Brummendorf","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2026.101366_bb0055","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.blre.2026.101366_bb0060","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"issue":"20","key":"10.1016\/j.blre.2026.101366_bb0065","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101366_bb0070","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","article-title":"Expert opinion\u2014management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2026.101366_bb0075","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.blre.2026.101366_bb0080","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.blre.2026.101366_bb0085","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.blre.2026.101366_bb0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/ajh.25306","article-title":"Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY","volume":"94","author":"Hehlmann","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2026.101366_bb0095","author":"Friends of Cancer Research"},{"issue":"1","key":"10.1016\/j.blre.2026.101366_bb0100","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1186\/s12885-019-6039-9","article-title":"Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis","volume":"19","author":"Tang","year":"2019","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.blre.2026.101366_bb0105","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","article-title":"Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase","volume":"30","author":"Guerin","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.blre.2026.101366_bb0115","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"Geissler","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2026.101366_bb0120","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","article-title":"Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs","volume":"34","author":"Sharf","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.blre.2026.101366_bb0125","first-page":"597","article-title":"Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey","volume":"111","author":"Lang","year":"2026","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2026.101366_bb0130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","article-title":"The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors","volume":"2016","author":"Efficace","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"14","key":"10.1016\/j.blre.2026.101366_bb0135","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101366_bb0140","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3904\/kjim.2021.158","article-title":"Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia","volume":"36","author":"Kim","year":"2021","journal-title":"Korean J Intern Med"},{"issue":"14","key":"10.1016\/j.blre.2026.101366_bb0145","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2026.101366_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph182111045","article-title":"Assessment of oral chemotherapy nonadherence in chronic myeloid leukemia patients using brief measures in community cancer clinics: a pilot study","volume":"18","author":"Davis","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"23","key":"10.1016\/j.blre.2026.101366_bb0155","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1182\/blood.2024027944","article-title":"Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: does dose matter?","volume":"145","author":"Dalgetty","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2026.101366_bb0160","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 \u2013 common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.blre.2026.101366_bb0165","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1016\/S2352-3026(18)30051-6","article-title":"Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies","volume":"5","author":"Thanarajasingam","year":"2018","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101366_bb0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12885-021-07782-z","article-title":"Optimal biological dose: a systematic review in cancer phase I clinical trials","volume":"21","author":"Fraisse","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2026.101366_bb0175","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1200\/EDBK_319783","article-title":"Moving beyond 3+3: the future of clinical trial design","volume":"41","author":"Kurzrock","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.blre.2026.101366_bb0180","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/cncr.35021","article-title":"Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia","volume":"130","author":"Efficace","year":"2024","journal-title":"Cancer"},{"issue":"15 suppl","key":"10.1016\/j.blre.2026.101366_bb0185","article-title":"Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION","volume":"35","author":"Cortes","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2026.101366_bb0190","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjh.14829","article-title":"Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd","volume":"179","author":"Hughes","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2026.101366_bb0195","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/cpt.2956","article-title":"Response-based dosing for ponatinib: model-based analyses of the dose-ranging OPTIC study","volume":"114","author":"Hanley","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2026.101366_bb0200","doi-asserted-by":"crossref","first-page":"1146108","DOI":"10.3389\/fonc.2023.1146108","article-title":"Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: from clinical trials to real-life settings","volume":"13","author":"Cheng","year":"2023","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.blre.2026.101366_bb0205","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s00277-023-05394-0","article-title":"Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the bosutinib dose optimization (BODO) study","volume":"102","author":"Isfort","year":"2023","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101366_bb0210","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101366_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101196","article-title":"Chronic myeloid leukaemia: biology and therapy","volume":"65","author":"Wang","year":"2024","journal-title":"Blood Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2026.101366_bb0220","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1182\/blood-2024-194617","article-title":"U.S. expert consensus on defining intolerance to tyrosine kinase inhibitor treatment in chronic phase chronic myeloid leukemia (CML)","volume":"144","author":"Atallah","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2026.101366_bb0225","series-title":"Presented at: 86th Annual Meeting of the Japanese Society of Hematology, 2024. October 11\u201313; Kyoto, Japan","article-title":"Future perspectives on frontline therapy in CML and treatment-free remission","author":"DDHT","year":"2024"},{"issue":"17","key":"10.1016\/j.blre.2026.101366_bb0230","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2026.101366_bb0235","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s11136-021-02794-5","article-title":"Health state utility and quality of life measures in patients with chronic myeloid leukemia in France","volume":"30","author":"Foulon","year":"2021","journal-title":"Qual Life Res"},{"issue":"16","key":"10.1016\/j.blre.2026.101366_bb0240","doi-asserted-by":"crossref","first-page":"17239","DOI":"10.1002\/cam4.6296","article-title":"Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia","volume":"12","author":"Chen","year":"2023","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.blre.2026.101366_bb0245","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00432-019-02894-3","article-title":"Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia","volume":"145","author":"Cortes","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2026.101366_bb0250","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-020-04018-1","article-title":"Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia","volume":"99","author":"Brummendorf","year":"2020","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.blre.2026.101366_bb0255","first-page":"446","article-title":"Patient-reported toxicity symptoms during tyrosine kinase inhibitor treatment in chronic myeloid leukemia: a systematic review and meta-analysis","volume":"33","author":"Smit","year":"2025","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.blre.2026.101366_bb0260","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.clml.2018.04.005","article-title":"Considerations for treatment-free remission in patients with chronic myeloid leukemia: a joint patient-physician perspective","volume":"18","author":"Saglio","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.blre.2026.101366_bb0265","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11912-021-01087-x","article-title":"Review of new-generation tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"23","author":"Shoukier","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"10.1016\/j.blre.2026.101366_bb0270","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40261-023-01329-9","article-title":"Maximizing the value of chronic myeloid leukemia management using tyrosine kinase inhibitors in the USA: potential determinants and consequences of healthcare resource utilization and costs, with proposed optimization approaches","volume":"44","author":"Lipton","year":"2024","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.blre.2026.101366_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - what to look for when treatment-free remission is not an option","volume":"56","author":"Lipton","year":"2022","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.blre.2026.101366_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10030515","article-title":"Dose optimization of tyrosine kinase inhibitors in chronic myeloid leukemia: a new therapeutic challenge","volume":"10","author":"Iurlo","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.blre.2026.101366_bb0285","article-title":"Navigating the management of chronic phase CML in the era of generic BCR::ABL1 tyrosine kinase inhibitors","volume":"22","author":"Haddad","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"issue":"10","key":"10.1016\/j.blre.2026.101366_bb0290","doi-asserted-by":"crossref","first-page":"e849","DOI":"10.1016\/S2352-3026(23)00173-4","article-title":"Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures","volume":"10","author":"Smit","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.blre.2026.101366_bb0295","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2025.2556506","article-title":"Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phase","volume":"30","author":"Atallah","year":"2025","journal-title":"Hematology"},{"issue":"5","key":"10.1016\/j.blre.2026.101366_bb0300","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S2352-3026(22)00045-X","article-title":"Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies","volume":"9","author":"Thanarajasingam","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.blre.2026.101366_bb0305","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications","volume":"117","author":"Pinilla-Ibarz","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2026.101366_bb0310","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3324\/haematol.2016.159848","article-title":"Research in the heart of hematology: chronic myeloid leukemia 2017","volume":"102","author":"Hehlmann","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.blre.2026.101366_bb0315","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/COC.0000000000000818","article-title":"Interventions to improve adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review","volume":"44","author":"Heiney","year":"2021","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2026.101366_bb0320","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-025-01242-8","article-title":"Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study","volume":"15","author":"Busque","year":"2025","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.blre.2026.101366_bb0325","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1182\/blood-2013-01-477687","article-title":"Measuring the symptom burden associated with the treatment of chronic myeloid leukemia","volume":"122","author":"Williams","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101366_bb0330","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3324\/haematol.2013.093724","article-title":"Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia","volume":"99","author":"Efficace","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2026.101366_bb0335","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","article-title":"Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV","volume":"126","author":"Saussele","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2026.101366_bb0340","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ajh.26463","article-title":"Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study","volume":"97","author":"Dahlen","year":"2022","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.blre.2026.101366_bb0345","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-012-1458-6","article-title":"Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC quality of life group","volume":"91","author":"Efficace","year":"2012","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.blre.2026.101366_bb0350","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1002\/cam4.1808","article-title":"A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors","volume":"7","author":"Zulbaran-Rojas","year":"2018","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.blre.2026.101366_bb0355","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/bmjebm-2023-112462","article-title":"Patient-reported effects of hospital-wide implementation of shared decision-making at a university medical Centre in Germany: a pre-post trial","volume":"29","author":"Scheibler","year":"2024","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.blre.2026.101366_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic myeloid leukemia: modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2026.101366_bb0365","article-title":"Patient and physician perspectives of unmet needs in CML - designing the CML SUN survey","volume":"138","author":"Pemberton-Whiteley","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2026.101366_bb0370","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.leukres.2010.10.017","article-title":"Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed","volume":"35","author":"Eliasson","year":"2011","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.blre.2026.101366_bb0375","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/10428194.2020.1838509","article-title":"Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia","volume":"62","author":"Efficace","year":"2021","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X26000056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:09:38Z","timestamp":1788221378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X26000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":74,"alternative-id":["S0268960X26000056"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2026.101366","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Underreported and underreviewed: Addressing the gaps in TKI tolerability literature for chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2026.101366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101366"}}